{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-135281","form_type":"8-K","ticker":null,"cik":"0001505512","company_name":"Regulus Therapeutics Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.720087+00:00","generated_at":"2026-06-02T05:36:45.492426+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Regulus Q1 net loss $8.5M; cash $107.7M; RGLS8429 cohort 4 dosed","bullets":["Net loss of $8.5M ($0.29/shr) vs $7.1M ($0.42/shr) in Q1 2023.","Cash, equivalents & investments $107.7M at Mar 31, 2024; runway into H1 2026.","Initiated 4th & final cohort of Phase 1b MAD trial for RGLS8429 in ADPKD; topline from cohort 3 expected mid-2024.","Closed oversubscribed $100M private placement in Mar 2024 with new and existing institutional investors.","R&D expense $6.0M (up 22% YoY); G&A expense $2.8M (up 17% YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-135281","json":"https://secwatch.observer/filing/0001193125-24-135281.json","markdown":"https://secwatch.observer/filing/0001193125-24-135281.md","text":"https://secwatch.observer/filing/0001193125-24-135281.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1505512/000119312524135281/0001193125-24-135281-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1505512/000119312524135281/d791133d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:36:45.492426+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"432bbd1860b9d1915f25793505b23cccdb532c74","claim":"Regulus Therapeutics Inc. reported the first quarter ended March 31, 2024 results: net income $8.5 million, or $0.29 per share (basic and diluted), EPS $0.29 per share (basic and diluted).","evidence_excerpt":"Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1505512/000119312524135281/0001193125-24-135281-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"$8.5 million, or $0.29 per share (basic and diluted)"},{"label":"EPS","value":"$0.29 per share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}